Population aging is a global phenomenon, and while not as critical as finding cures for cancer or rare diseases, anti-aging therapies – a branch of regenerative medicine – have consistently intrigued researchers, investors, and biotech entrepreneurs for the last decade.

If there’s one thing that remains constant in biotech, it’s the ability of companies to adapt and evolve relative to available resources and current limitations….

With much of biotech news focusing on a down market and several prominent companies having recently failed to hit primary endpoints, it begs the question…

The word ‘protein’ often makes one think of a steak dinner or a smoothie, but in the world of biotech protein therapeutics are forming the backbone of next-generation therapies and novel medicines…

The word ‘protein’ often makes one think of a steak dinner or a smoothie, but in the world of biotech protein therapeutics are forming the backbone of next-generation therapies and novel medicines…

Last week, biotech news hubs were ablaze with the unexpected departure of Hal Barron, GSK’s R&D chief. In August Barron will take the helm as CEO of Altos Labs, headquartered in San Francisco, Californa…

With JPM 2022 having finished up last week, new standout partnerships between promising biotech companies and profitable big pharma show that reciprocity between players…

New developments in the continually evolving field of microbiome research have risen out of young startup Wild Biotech, a company whose focus is…

Synthetic biology is a new area of research and development that applies engineering principles to biological processes. Synthetic biology enables…